AVKARE Lovastatin Tablets Recall: Failed Dissolution Testing
AVKARE recalls 40mg Lovastatin tablets with failed dissolution testing. Consumers should contact manufacturer for details.
Lower-risk recall
Failed Dissolution Specifications: Low out of specification results for dissolution during annual stability testing.
Contact the company
What happened, in plain English
AVKARE has recalled 40mg Lovast:at tablets that failed dissolution testing. This means the medication may not work as intended, potentially affecting treatment effectiveness. Read more at govinfonow.com/recall/40957-avkare-lovastatin-tablets-recall-failed-dissolution-testing.
Source Summary by GovInfoNow · govinfonow.com/recall/40957-avkare-lovastatin-tablets-recall-failed-dissolution-testing · Updated October 7, 2026 · FDA enforcement record: FDA #D-0222-2018
Cite this page
“AVKARE Lovastatin Tablets Recall: Failed Dissolution Testing.” GovInfoNow, updated October 7, 2026. https://govinfonow.com/recall/40957-avkare-lovastatin-tablets-recall-failed-dissolution-testing. Based on FDA recall #D-0222-2018 (https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-0222-2018%22&limit=1).
Why it’s dangerous
The tablets failed dissolution testing during stability checks. This means the medication may not dissolve properly in the body, reducing effectiveness. However, the recall does not indicate immediate harm to users.
Who’s affected
People who have the specific lot number (15270) of AVKARE Lovastatin tablets. Those taking cholesterol medication are most at risk.
How to tell if you have this one
Check for the lot number 15270 on the carton. The product is a 40mg Lovastatin tablet package with NDC 50268-512-15.
- Brand
AVKARE- Category
Drug
What to do — step by step
Check Product Details
Look for lot number 15270 on the carton to confirm if your product is affected.
Where it went and when
Where it was distributed
Distributed nationwide.
FDA distribution: “Nationwide in the USA” States read from FDA’s own wording; “not listed” means the notice does not name it.
Distributed nationwide.
Recall timeline
FDA terminated this recall 2.3 years after the firm started it.
- Firm started the recall
- FDA classified it Class II
- Published in FDA’s Enforcement Report
- FDA terminated the recall
Dates from the agency record only; steps without a date are left out.
Similar recalls
Latest drug recalls
Keep exploring
Where this comes from
The facts (hazard, remedy, dates, manufacturer) are pulled from the official FDA recall record. The plain-language summary and step-by-step checklist are written by GovInfoNow to make the official notice easier to act on — they don’t replace it.
- Official source: FDA Recall #D-0222-2018 (January 3, 2018) — FDA publishes no per-recall page; this is the official machine-readable enforcement record. Search FDA recalls for D-0222-2018 to see it in context.
- Plain-language summary written by qwen3:4b on October 7, 2026, from the official record above. Not reviewed by a person — if it conflicts with the FDA notice, the notice is correct. Report an error on this page.
- GovInfoNow is an independent service and is not a government agency. We republish official FDA recall data; we don’t issue, amend or administer recalls.